Table 2.
Adjusted hazards ratios and 95% confidence intervals for the risk of ischemic stroke and hemorrhagic stroke across terminal nodes in the Kailuan I participants with low-density lipoprotein cholesterol concentrations < 70 mg/dL
| Ischemic stroke, HR (95%CI) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Node1 | Node2 | Node3 | Node4 | Node5 | Node6 | Node7 | Node8 | Node9 | |
| Case/person-years | 15/28,515 | 37/15,483 | 78/14,743 | 60/10,818 | 8/1026 | 119/12,021 | 10/547 | 53/2553 | 8/143 |
| LDL-C ± SD, mg/dL | 56.8 ± 10.9 | 57.3 ± 10.8 | 64.6 ± 3.03 | 57.7 ± 8.76 | 55.6 ± 11.9 | 50.1 ± 6.48 | 19.2 ± 8.90 | 20.3 ± 8.53 | 20.6 ± 9.63 |
| Multivariate modela | 1.00 (reference) | 3.73 (2.01, 6.92) | 7.07 (3.98, 12.6) | 7.38 (4.05, 13.4) | 8.44 (3.04, 23.4) | 13.0 (7.41, 22.7) | 20.8 (7.86, 54.8) | 23.1 (12.4, 43.1) | 76.3 (30.2, 192.7) |
| Excluding eGFR < 60 ml/min/1.73 m2 | 1.00 (reference) | 3.60 (1.94, 6.70) | 6.06 (3.37, 10.9) | 7.10 (3.85, 13.1) | 8.86 (3.19, 24.6) | 12.8 (7.30, 22.4) | 18.9 (6.69, 53.4) | 24.6 (13.1, 46.2) | 62.2 (23.3, 166.3) |
| Excluding Framingham risk score > 30% | 1.00 (reference) | 3.82 (2.02, 7.23) | 6.41 (3.38, 12.1) | 6.71 (3.29, 13.7) | 10.4 (3.74, 29.2) | 12.3 (6.74, 22.4) | 24.2 (6.74, 86.6) | 23.3 (11.2, 48.1) | 76.8 (24.7, 238.3) |
| Excluding BMI < 18.5 kg/m2 | 1.00 (reference) | 3.75 (2.02, 6.94) | 7.01 (3.94, 12.5) | 7.51 (4.12, 13.7) | 8.37 (3.02, 23.2) | 13.0 (7.45, 22.8) | 21.9 (8.29, 57.9) | 23.1 (12.4, 43.1) | 74.5 (29.5, 188.2) |
| Excluding blood pressure-lowering drugs | 1.00 (reference) | 3.48 (1.85, 6.56) | 6.49 (3.50, 12.0) | 7.24 (3.88, 13.5) | 9.26 (3.32, 25.8) | 11.0 (6.10, 19.8) | 22.0 (8.24, 59.0) | 22.3 (11.5, 43.2) | 52.1 (16.8, 161.5) |
| Excluding glucose-lowering drugs | 1.00 (reference) | 3.69 (1.98, 6.87) | 6.92 (3.87, 12.4) | 7.81 (4.27, 14.3) | 9.35 (3.36, 26.0) | 13.1 (7.49, 23.0) | 18.0 (6.39, 50.7) | 21.8 (11.6, 40.9) | 63.1 (23.7, 168.0) |
| Hemorrhagic stroke, HR (95%CI) | |||||||||
| Node1 | Node2 | Node3 | Node4 | Node5 | Node6 | ||||
| Case/person-years | 13/41,704 | 13/4435 | 19/10,553 | 75/27,377 | 12/2102 | 13/739 | |||
| LDL-C ± SD, mg/dL | 59.3 ± 7.25 | 28.9 ± 9.75 | 58.8 ± 7.51 | 57.8 ± 8.82 | 19.9 ± 8.60 | 20.2 ± 8.03 | |||
| Multivariate modela | 1.00 (reference) | 4.40 (2.07, 9.33) | 6.59 (3.55, 12.2) | 5.41 (2.22, 13.2) | 9.74 (3.84, 24.7) | 41.7 (17.2, 101.6) | |||
| Excluding eGFR < 60 ml/min/1.73 m2 | 1.00 (reference) | 4.58 (2.13, 9.85) | 6.55 (3.52, 12.2) | 4.68 (1.84, 11.9) | 9.98 (3.78, 26.4) | 37.5 (15.3, 91.6) | |||
| Excluding Framingham risk score > 30% | 1.00 (reference) | 5.09 (2.02, 12.8) | 5.01 (2.51, 9.99) | 4.11 (1.52, 11.1) | 10.7 (3.25, 35.2) | 21.3 (6.86, 65.9) | |||
| Excluding BMI < 18.5 kg/m2 | 1.00 (reference) | 4.52 (2.13, 9.59) | 6.46 (3.48, 12.0) | 4.85 (1.91, 12.3) | 9.71 (3.82, 24.7) | 42.6 (17.4, 104.2) | |||
| Excluding blood pressure-lowering drugs | 1.00 (reference) | 3.55 (1.57, 8.03) | 5.39 (2.78, 10.4) | 5.03 (2.05, 12.4) | 7.73 (2.60, 23.1) | 34.0 (12.8, 89.9) | |||
| Excluding glucose-lowering drugs | 1.00 (reference) | 4.56 (2.14, 9.69) | 6.42 (3.44, 12.0) | 5.52 (2.26, 13.5) | 10.2 (4.00, 25.8) | 38.1 (15.2, 95.4) | |||
Abbreviations: HR, hazard ratio; CI, confidence interval; LDL-C, low-density lipoprotein cholesterol; SD, standard deviation; eGFR, estimated glomerular filtration rate; BMI, body mass index
aAll models were adjusted for sex (men or women), age (year), physical activity (inactive, moderately active, or vigorously active), smoking and drinking status (never, former, occasional or daily), blood pressure status during follow-up (well-controlled or poorly controlled), blood glucose status during follow-up (well-controlled or poorly controlled), body mass index (kg/m2), urine protein (negative, trace, +, ++, or +++), heart rate (bpm), triglyceride (mg/dL), high-density lipoprotein cholesterol (mg/dL), low-density lipoprotein cholesterol (mg/dL), estimated glomerular filtration rate (ml/min/1.73 m2), and high-sensitivity C-reactive protein (mg/L)